AI summary by TwinMind
Ozempic and Wegovy: All you need to know
Sabine Hossenfelder
15m 9s
Drug Approval and Market Impact
- 2021: US FDA approved Wegovy (semaglutide) for weight loss
- Prescriptions increased 2,000% from 2019-2022 in USA (Komodo Health data)
- Drug shortages reported: USA (FDA shortage list), UK, Ireland, Canada, China, Belgium
- Hollywood widespread use with public denials
- Elon Musk announced 30-pound weight loss on Twitter, reported "next level burps"
Drug Mechanism and Composition
- Semaglutide: active ingredient in both Wegovy (weight loss) and Ozempic (diabetes)
- Wegovy: higher dose formulation
- Ozempic: approved 2017 for type 2 diabetes
- Manufacturer: Danish company Novo Nordisk
- Mimics GLP-1 (glucagon-like peptide) hormone
- Naturally produced in gastrointestinal tract
- Triggers insulin production in pancreas
- Reduces blood sugar levels
- Weight loss mechanism:
- Slows stomach emptying → prolonged fullness
- Acts in brain to reduce hunger
- Makes food intake reduction easier
Administration Methods
- Primary: Weekly injection (pre-filled pen)
- Injection sites: upper arm, thigh, belly
- Start low dose, gradually increase
- Alternative: Daily pills
- More cumbersome: empty stomach, specific water amount, 30-minute wait
- Historically less effective weight loss
- Recent study: higher oral doses = similar results to injections
Clinical Trial Results
- 2021 international study (Novo Nordisk-related):
- Nearly 2,000 adults, BMI 30+, non-diabetic
- 68-week treatment period
- Lifestyle interventions: 500 calorie reduction/day, 150 minutes exercise/week
- Results after 68 weeks:
- Semaglutide group: 15% average weight loss
- Placebo group: 2.4% weight loss
Competing Drugs
- Tirzepatide (Mounjaro by Eli Lilly):
- Weekly injection
- Approved 2022 for diabetes (USA and EU)
- Not yet approved for weight loss
- Higher weight loss: up to 21%
- Higher adverse effects: 7% stopped treatment on high dose
- Retatrutide:
- Phase 2 trial results presented weeks ago
- Up to 24% weight loss on highest dose
- Mouse studies showed mostly fat loss
Side Effects and Concerns
- Common adverse reactions (>5% patients):
- Nausea, vomiting, diarrhea, abdominal pain, constipation
- Side effects gradually become milder
- Some experience severe nausea/fatigue requiring discontinuation
- Long-term concerns under investigation:
- Pancreatic cancer, thyroid cancer
- Retinal damage, increased self-harm risk
- Weight composition concerns:
- Only 60% of weight lost was fat (vs recommended 75%)
- Violates "quarter FFM rule" for healthy dieting
- Problematic for women (higher natural body fat) and elderly (low muscle mass)
Treatment Discontinuation Effects
- Weight regain after stopping:
- Semaglutide users: regained 2/3 of lost weight after 1 year
- Placebo users: regained all weight
- Blood pressure improvements also faded
Usage Patterns and Access Issues
- Demographics: >34% users are women
- Off-label use for special occasions (weddings, vacations)
- Access problems:
- Diabetics can't get Ozempic
- Obese patients can't get Wegovy
- Non-medical users with money access drugs faster
- Government interventions:
- Australia limited Ozempic to diabetes treatment until December 2023
Economic Impact
- Monthly cost in USA: >$1,000
- International pricing (2022 data):
- France: $242/month
- Turkey: $95/month
- US insurance coverage:
- Some state Medicaid programs cover treatment
- Private insurance partial coverage
- Medicare prohibited by law from covering weight loss prescriptions
- Biden Administration committed to addressing obesity
- Potential US costs if Medicare covers:
- 42% of American adults obese
- Could reach hundreds of billions annually
- Economic offset: obesity's detrimental health effects cost similar magnitude
Social and Ethical Implications
- Moral dilemma: brain wiring determines weight management difficulty
- Some people's natural hunger leads to healthy weight
- Others face choice: suffer from hunger or suffer from being overweight
- Prescription-only access creates inequity
- Resentment from those who achieved weight loss through diet/exercise
- Ozempic users labeled as "lazy"
- Body positivity movement tensions:
- Movement promotes body acceptance
- Semaglutide reveals many obese people prefer weight loss over acceptance
- Creates exclusive "weight loss game" due to cost/availability
- Potential positive outcome: easier weight loss for non-medical users may reduce appeal
Future Outlook
- More drugs in development may reduce costs
- Potential shift in societal attitudes toward weight loss
- Ongoing research into long-term effects and optimal formulations
